New anemia drug for MDS and myeloma patients shows early promise but trial halted
NCT ID NCT04582539
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tested a daily pill called INCB000928 for people with anemia caused by myelodysplastic syndromes (MDS) or multiple myeloma. The goal was to see if it was safe and could raise red blood cell levels, reducing the need for transfusions. The trial was terminated early after enrolling only 22 participants, so we have limited information on how well it works.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
INCB000928
What this could lead to
If successful, this drug could help reduce or eliminate the need for blood transfusions in people with anemia from MDS or multiple myeloma.
What could go wrong
This was a very early (Phase 1/2) trial that was terminated before completion, so we have little data on safety or effectiveness. The drug may not work or could have side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ANEMIA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Azienda Ospedaliero-Universitaria Careggi (Aouc)
Florence, 50134, Italy
-
Barbara Ann Karmanos Cancer Hospital
Detroit, Michigan, 48201, United States
-
Centre Hospitalier Universitaire de Nantes (Chu de Nantes) - Hotel-Dieu
Nantes, 44093, France
-
Comitato Di Bioetica Della Fondazione Irccs Policlinico San Matteo
Pavia, 27100, Italy
-
Florida Cancer Specialists
Sarasota, Florida, 34232, United States
-
Hospices Civils de Lyon Centre Hospitalier Lyon Sud
Pierre-Bénite, 69310, France
-
Institut Gustave Roussy
Villejuif, 94800, France
-
Irccs Istituto Clinico Humanitas
Rozzano, 20089, Italy
-
L Azienda Ospedaliero-Universitaria Di Bologna Policlinico S. Orsola - Malpighi
Bologna, 40138, Italy
-
Md Anderson Cancer Center
Houston, Texas, 77030, United States
-
Stanford Cancer Center
Palo Alto, California, 94304, United States
-
Tulane Comprehensive Cancer Center
New Orleans, Louisiana, 70112, United States
-
University of Cincinnati
Cincinnati, Ohio, 45219, United States
-
University of Miami
Miami, Florida, 33136, United States
-
Vanderbilt University Medical Center
Nashville, Tennessee, 37232, United States